These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 36122506)

  • 1. Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities.
    Fu D; Hu Z; Xu X; Dai X; Liu Z
    Transl Oncol; 2022 Dec; 26():101510. PubMed ID: 36122506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
    Prossomariti A; Piazzi G; Alquati C; Ricciardiello L
    Cell Mol Gastroenterol Hepatol; 2020; 10(3):491-506. PubMed ID: 32334125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pleiotropic Role of Long Non-Coding RNAs in the Modulation of Wnt/β-Catenin and PI3K/Akt/mTOR Signaling Pathways in Esophageal Squamous Cell Carcinoma: Implication in Chemotherapeutic Drug Response.
    Sharma U; Murmu M; Barwal TS; Tuli HS; Jain M; Prakash H; Kaceli T; Jain A; Bishayee A
    Curr Oncol; 2022 Mar; 29(4):2326-2349. PubMed ID: 35448163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
    Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
    Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/β-Catenin and PI3K/Akt Signaling.
    Kang DW; Lee BH; Suh YA; Choi YS; Jang SJ; Kim YM; Choi KY; Min DS
    Clin Cancer Res; 2017 Dec; 23(23):7340-7350. PubMed ID: 28939743
    [No Abstract]   [Full Text] [Related]  

  • 6. Crocin molecular signaling pathways at a glance: A comprehensive review.
    Boozari M; Hosseinzadeh H
    Phytother Res; 2022 Oct; 36(10):3859-3884. PubMed ID: 35989419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways.
    Yang XL; Lin FJ; Guo YJ; Shao ZM; Ou ZL
    Onco Targets Ther; 2014; 7():1033-42. PubMed ID: 24966685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma.
    Dimri M; Satyanarayana A
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32093152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
    Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
    Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers.
    Reddy D; Kumavath R; Tan TZ; Ampasala DR; Kumar AP
    Life Sci; 2020 Jan; 241():117147. PubMed ID: 31830480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.
    Mafi S; Mansoori B; Taeb S; Sadeghi H; Abbasi R; Cho WC; Rostamzadeh D
    Front Immunol; 2021; 12():774103. PubMed ID: 35250965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
    Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
    J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Role and Clinicopathological Significance of AEG-1 in Different Cancer Types: A Concise Review.
    Sriramulu S; Sun XF; Malayaperumal S; Ganesan H; Zhang H; Ramachandran M; Banerjee A; Pathak S
    Cells; 2021 Jun; 10(6):. PubMed ID: 34203598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review.
    Shahcheraghi SH; Tchokonte-Nana V; Lotfi M; Lotfi M; Ghorbani A; Sadeghnia HR
    Curr Pharm Des; 2020; 26(15):1729-1741. PubMed ID: 32003685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
    Raith F; O'Donovan DH; Lemos C; Politz O; Haendler B
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
    Stefani C; Miricescu D; Stanescu-Spinu II; Nica RI; Greabu M; Totan AR; Jinga M
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
    Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
    Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma.
    Barzegar Behrooz A; Talaie Z; Jusheghani F; Łos MJ; Klonisch T; Ghavami S
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.